---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000812943.md"
description: "📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Eli Lilly(LLY.US) Eli Lilly's Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:➤  𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 reports positive 𝗣𝗵𝗮𝘀𝗲 𝟯 results for retatrutide.➤  𝗧𝗥𝗜𝗨𝗠𝗣𝗛-𝟮 achieved average 𝟮𝟬.𝟴% (𝟰𝟵.𝟲 𝗹𝗯𝘀) weight loss at 𝟭𝟮 mg.➤  Placebo group lost 𝟰.𝟬% (𝟵.𝟯 𝗹𝗯𝘀) in 𝗧𝗥𝗜𝗨𝗠𝗣𝗛-𝟮.➤  𝗔𝟭𝗖 declined by up to 𝟭.𝟲% from a 𝟳.𝟳% baseline.➤  𝗧𝗥𝗜𝗨𝗠𝗣𝗛-𝟯 achieved average 𝟮𝟮.𝟲% (𝟱𝟱.𝟴 𝗹𝗯𝘀) weight loss at 𝟭𝟮 mg.➤  Retatrutide reduced triglycerides by 𝟯𝟳.𝟬%, non-HDL cholesterol by 𝟭𝟲.𝟱%.➤  Systolic blood pressure declined by an average of 𝟵.𝟯 mmHg.➤  𝗠𝗔𝗖𝗘 analyses did not reach statistical significance as confidence intervals crossed 𝟭.𝟬.➤  Lilly plans to submit an 𝗙𝗗𝗔 Biologics License Application in 𝗤𝟭 𝟮𝟬𝟮𝟳."
datetime: "2026-07-23T10:52:04.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000812943.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000812943.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000812943.md)
author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)"
generator: "portal-rs"
---

# 📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Eli Lilly(LLY.US) Eli Lilly's Retatrut…


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**